Labcorp will pick up specialty testing in women’s health as well as a blood test that assesses the likelihood of finding aggressive prostate cancer before a biopsy decision.
Labcorp to buy BioReference assets for up to $872M
Labcorp will pick up specialty testing in women’s health as well as a blood test that assesses the likelihood of finding aggressive prostate cancer before a biopsy decision.